Drugs / CAR138 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03672318 | Jan 2019 → Oct 2024 overdue | plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR138 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03672318 ↗ |
| Action | Deplete | “These CD138 chimeric (combination) receptor-activated T cells seem to kill some of the tumor” NCT03672318 ↗ |
| Modality | Cell therapy | “CAR T cells” NCT03672318 ↗ |
| Route | Intravenous | “CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.” NCT03672318 ↗ |